Category - Developments

Developments

Incisionless TULSA Procedure for prostate cancer demonstrated statistically significant superior penile length preservation compared to Robotic Radical Prostatectomy at 1 month

The title of Profound Medical’s (NASDAQ:PROF; TSX:PRN) press release today, “Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial,” playfully set the tone for its reporting of a sensitive subject: penile...

July 24, 2026

Developments

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Valion Bio (NASDAQ: VBIO) has announced that the regulatory dossier for its lead candidate, Entolimod for acute radiation syndrome (ARS), has been accepted by Ukraine’s Ministry of Health (MoH) for formal review...

July 22, 2026

Developments

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Valion Bio (NASDAQ: VBIO) has announced a major clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center, one of the world’s leading hospitals, to evaluate...

July 20, 2026

Developments

Casp-Aid appoints Mika Guerard as VP, Head of Drug Development

Closely held Casp-Aid has appointed Mika (Kimiaka C.) Guerard, PhD, MBA, as VP, Head of Drug Development as it makes final preparations to launch a Phase IIb clinical trial evaluating its lead small molecule, CIM765, in...

July 20, 2026

Developments

LIR and OH sign agreement to advance roadmap for transdermal obesity pipeline

LIR Life Sciences (CSE: SKNY; OTCPK: BBCMF) has announced that it has entered into a services agreement with closely held Oxygen Handel GmbH (OH), a specialized preclinical and regulatory development organization, to...

July 17, 2026

Developments

Dimerix acquires Phase 2-ready asset for acute kidney injury

Dimerix (ASX: DXB) has announced that it has acquired DMX-652 for all indications from closely held Mission Therapeutics, expanding its pipeline in rare kidney disease. DMX-652 is a novel first and best-in-class...

July 17, 2026

Developments

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Mobia Medical (NASDAQ: MOBI) has announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the peer-reviewed journal of the American Academy of Neurology, demonstrating that...

July 15, 2026

Developments

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Fractyl Health (NASDAQ: GUTS) has announced positive one-year results from its REMAIN-1 Midpoint Cohort reinforcing the potential of the Revita DMR System to be the first durable procedural therapy for post-GLP-1 weight...

July 15, 2026

Developments

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure will be highlighted in several presentations by leading physicians at the...

July 15, 2026

Developments

Myricx to be acquired by Novartis for $1.5B

Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis (NYSE: NVS) for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. The acquisition...

July 14, 2026

Category - Developments

Subscribe